Infiltrating duct carcinomas, also known as invasive ductal carcinomas, are a type of breast cancer that arises from the cells lining the milk ducts within the breast. This type of carcinoma is the most common form of breast cancer, accounting for about 80% of all cases.
The term "infiltrating" refers to the aggressive nature of this cancer, as it invades the surrounding breast tissues beyond the milk ducts. Unlike non-invasive or in situ ductal carcinomas, infiltrating duct carcinomas have the ability to spread to other parts of the body, making them potentially more dangerous and harder to treat.
Pathologically, infiltrating duct carcinomas are characterized by the presence of cancer cells that infiltrate the surrounding breast tissue, forming irregular masses or lumps. These cancer cells can invade nearby lymph nodes and blood vessels, allowing them to potentially metastasize, or spread, to distant organs such as the bones, liver, or lungs.
Symptoms of infiltrating duct carcinomas may include a breast lump, breast pain or discomfort, nipple discharge, or changes in the size, shape, or texture of the breast. However, these symptoms can also be associated with other benign breast conditions, so further testing is required to confirm the presence of cancer.
Treatment options for infiltrating duct carcinomas depend on various factors such as the size of the tumor, its stage, and the individual patient's health. Common treatment approaches may involve surgery to remove the tumor, radiation therapy, chemotherapy, and targeted therapies. The prognosis and long-term outcomes for infiltrating duct carcinomas vary depending on factors such as the stage and grade of the cancer, as well as the individual's age and overall health. Regular screening and early detection are crucial in improving the prognosis and reducing the mortality rates
